Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.380
-0.010 (-0.72%)
Mar 9, 2026, 2:50 PM EDT - Market open
Company Description
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States.
The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Tiziana Life Sciences Ltd
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Mar 24, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Ivor Elrifi |
Contact Details
Address: 14/15 Conduit Street London, W1S 2XJ United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | TLSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723069 |
| CUSIP Number | 88875G101 |
| ISIN Number | BMG889121031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivor R. Elrifi Ph.D. | Chief Executive Officer and Executive Director |
| Gabriele Marco Antonio Cerrone M.B.A. | Founder and Executive Chairman |
| Keeren Shah | Chief Operating Officer and Chief Financial Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 6-K | Report of foreign issuer |
| Feb 20, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 22, 2026 | 424B5 | Filing |
| Jan 22, 2026 | AW | Amendment Withdrawal Request |
| Jan 21, 2026 | POS AM | Post-Effective amendments for registration statement |
| Jan 20, 2026 | 6-K | Report of foreign issuer |
| Jan 16, 2026 | 6-K | Report of foreign issuer |
| Jan 16, 2026 | 424B5 | Filing |
| Jan 16, 2026 | 6-K | Report of foreign issuer |
| Jan 9, 2026 | 6-K | Report of foreign issuer |